The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association between skin toxicities and treatment outcomes in patients with pancreatic cancer (PC) receiving erlotinib (E): Memorial Sloan-Kettering Cancer Center (MSKCC) experience.
Linh My Alejandro
No relevant relationships to disclose
Nelly G. Adel
No relevant relationships to disclose
Eileen Mary O'Reilly
No relevant relationships to disclose
Elyn Riedel
No relevant relationships to disclose
Mario E. Lacouture
Consultant or Advisory Role - Genentech; OSI Pharmaceuticals; Roche